| INTRODUC TI ON
A key feature of contemporary medicine is the incorporation of molecular information within clinical pathways to understand and act upon disease.
1 This is particularly visible within oncology, where it is anticipated that the identification of specific genetic alterations within tumours will lead to treatment regimes tailored to individual patients. 2 As an example of this novel approach, gene expression profiling may now be offered as part of routine National Health Service (NHS) breast cancer care for a subgroup of patients. This technique is used to assist decision making around adjuvant chemotherapy, a treatment administered following surgery to reduce the likelihood of cancer returning. For some early-stage breast cancers,* the predicted benefit of chemotherapy for preventing recurrence may be unclear when assessed on protein receptor status and tumour grade alone. Available as part of NHS care as of April 2015
(initially in England), the Oncotype DX test uses gene expression profiling to predict the risk of cancer recurrence in these patients and identify those who are most likely to benefit from adjuvant chemotherapy.
Oncotype DX assesses the activity of 21 genes in breast cancer tissue. The corresponding results are prognostic, indicating the likelihood of a woman's cancer returning within 10 years when treated with hormone therapy alone. The cancer is assigned a continuous "recurrence score" (from 0 to 100), and a risk category for recurrence: low (<18), intermediate (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) or high (≥31). 3 The recurrence score is a predictor of benefit from the addition of chemotherapy to hormone therapy for disease-free survival. 4 In clinical practice, both the score and risk categorization are used by clinicians and patients to assist chemotherapy decisions. For those positioned at low risk of recurrence, studies have suggested that these patients are unlikely to derive great benefit from adjuvant treatment. 5 Patients in this category are not recommended to proceed with chemotherapy, 6 which is itself associated with (sometimes severe) side-effects and suffering. 7 Chemotherapy is recommended for those patients with a high recurrence score, as it has been shown to bestow significant advantage for disease-free survival compared with hormone therapy alone. 4 For those placed in the intermediate category,
recommendations for chemotherapy are less clear (though a recent clinical trial has indicated that women with an intermediate score may be spared chemotherapy 8 ). In the case of an intermediate score, treatment recommendations often involve further discussions with the patient, alongside consideration of wider clinical parameters and patient preferences. 6, 9 In 2013, guidance published by the National Institute for Health and Care Excellence (NICE) acknowledged the uncertainties surrounding treatment decision making for patients with early-stage breast cancer of this type and recommended that Oncotype DX be adopted by the NHS:
Breast cancer patients face significant emotional and psychological strain when considering chemotherapy.
It can be particularly distressing for patients in whom the decision to have chemotherapy is unclear… Tools or tests that help people decide whether or not to have chemotherapy are likely to be greatly appreciated by patients.
3
Here, the availability of gene expression profiling is positioned as a positive development for individual patients, by "helping people to decide" whether to proceed to chemotherapy. Discerning who may (not) benefit most from chemotherapy is also important from a policy perspective, with the "over-treatment" of breast cancer having implications for health service costs and delivery. 3, 10 Though social scientific research has explored clinicians' experiences of interpreting gene expression tests 9 and their impact on professional roles and identity, 11 less attention has been given to the ways in which these tools feature in patient decision making with regards treatment, or the role they play in experiences of cancer more widely. This is important for policy and practice; it has been established that chemotherapy decisions are shaped by social contexts, familial relationships and wider health histories, but little is known about how novel prognostic techniques intersect with these. In this article, we explore some of these factors as articulated by women within online accounts.
Existing sociological research has shown that medical decision making by patients is complex and situated. Treatment decisions may be thought of as "distributed"
12
-shared amongst patients, their families, clinicians and wider social networks, and as occurring across time and space. 13 Although patient participation in decision making is advocated within medical practice, it has been reported that patients vary in the degree to which they wish to take full ownership over treatment decisions in health care. 14, 15 Alongside contemporary shifts in the provision of care, individuals are also seeking advice and support for medical decision making beyond the clinic through virtual platforms. 16 The Internet can be a source of second opinions, advice regarding symptoms or side-effects, and information about tests and treatments for those experiencing cancer. 17 Indeed, access to others' experiences of a shared health condition has been highlighted as a key aspect of online information seeking, with first person accounts of illness shaping treatment choices and the very experiences of ill health. 18 As categorizations of (some) cancers and treatment pathways become more diffuse, 
| Data
To gather online accounts of women's experiences, two authors (ER and JS) searched for the term "Oncotype" within publically ac- analytic memos, which were recorded alongside the text itself using the "comments" function.
Searches yielded a large amount of data. By way of example, one of the seven online forums featuring the word "Oncotype" 
| Data analysis
Analysis took a thematic approach, aligned with the analytic process described by Braun and Clarke. 
| Ethical considerations
Online methods of data collection for sociological research are subject to wider ethical guidelines associated with the discipline, with safeguarding the interests of those involved in or affected by the research remaining paramount. 24 However, the use of online mate- 
| FINDING S
In what follows, we show how the Oncotype DX test was represented by women using online forum spaces. We then go on to discuss how women described test results and their role in chemotherapy decision making, with this shaped by indirect experiences of cancer treatment, and sociocultural depictions of cancer and chemotherapy. Finally, we outline how users discussed the test in relation to inherent uncertainties with regards the success of treatment and possibility of cancer recurrence. In doing so, we highlight tensions between the claims of genomic testing to aid treatment decision making, and the uncertainties and anxieties which the procedure could provoke or leave unresolved. 
| Representations of gene expression testing within online environments

2016
Scepticism of these more widely used tools was also visible amongst others, with MayP (January 2017) describing these as "only a general indicator based on past recovery data that can be quite old."
In the same thread, Pumpkin noted that where "generalised tools could be very wrong," Oncotype DX is "an individual test for you," which she interpreted as providing more surety with regards her treatment decision.
Betty45, who had not experienced gene expression profiling herself but was living with a heart condition she attributed to chemotherapy, displayed a particularly positive view of the technology. She invoked a hopeful future by saying "I think the answer for a large percentage of us will be the Oncotype DX test which shows whether chemo will work or not" (Nov 2015). Some thus positioned the test as not only providing certainty, but also as having the potential to transform breast cancer care. 26, 27 Although this was not reflective of all users, with many also depicting the test not as a tool that eliminated guesswork, but one that "refined" guesswork, positive reflections on the test's role in decision making were visible throughout forum posts. In many cases, these could efface the complex and relational contexts within which decision making arose, which were also articulated within forum discussions. This is discussed further below.
| Gene expression testing and treatment decision making
Oncotype DX's production of a single figure to indicate recurrence risk, and corresponding recommendation to proceed (or not In many of these cases, the score became a powerful and direct representation of their current and possible future experiences of cancer, able to be shared with others within this online environment. None of us can see into the future, so we have to make a decision on the information we have. to shed light on the breadth and potential complexity of decision making in the context of a novel genomic technique. 37 The absence of in-depth narratives, with analysis focusing on short posts which were sometimes devoid of context, has also meant that we were not able to explore wider impacts on decision making in great depth.
| D ISCUSS I ON
Further research is required to learn more about how patients seek and share information with others, and the impact of online forum use itself on decision making about cancer treatment. This may offer guidance to patients and clinicians about how online forums might be best used at this difficult time. These issues are being addressed by complementing this online research with ongoing qualitative interviews.
| CON CLUS ION
This study of accounts of gene expression profiling has shed light on how women are engaging with and negotiating novel genomic techniques as they become integrated within routine cancer care in the UK, and the resources they draw on in this regard. Importantly for clinical practice, we have shown that the women represented in this research did not always interpret Oncotype DX scores straightforwardly, with these results taking on varying significance according to factors including personal encounters with cancer, and potential regret for declining treatment. This emphasizes the importance of holistic treatment decision making between patients and clinicians, which may engage with loved ones' experiences of the disease, "gut feelings," emotions and anticipated futures.
Online forums have proved to be a valuable resource to explore perceptions of gene expression profiling as articulated by women in the midst of chemotherapy choices. These are also emblematic of the contemporary distribution of decision making, which has the potential to become reconfigured as genomic techniques and "personalized" treatment regimes become further integrated within clinical care. In-depth qualitative research will provide deeper insight into the emotional and embodied elements of these treatment choices, and their interplay with genomic techniques alongside more established means of informing treatment decisions in cancer care.
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